SEC Form SC 13G/A filed by Prothena Corporation plc (Amendment)
$PRTA
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $4.00 | Neutral → Underperform | BofA Securities |
| 5/27/2025 | Outperform → Perform | Oppenheimer | |
| 5/27/2025 | $6.00 | Buy → Hold | Jefferies |
| 5/27/2025 | Overweight → Neutral | Cantor Fitzgerald | |
| 12/20/2024 | $40.00 | Buy | Chardan Capital Markets |
| 1/30/2024 | $68.00 → $38.00 | Buy → Neutral | BofA Securities |
| 12/12/2023 | $62.00 | Buy | Deutsche Bank |
| 4/24/2023 | $80.00 | Outperform | SVB Securities |
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena's Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb played a significant role in which she made key contributions to the Company's vision and strategy. "I would like to thank Paula for her many contributions during the past six years. As a biotechnology executive with wide-ranging global development, business strategy and commercial expertise, she provided valuable insights to the board and lea
TDP-43 CYTOPE® preclinical data demonstrates the potential of Prothena's CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting of intracellular disease pathways Systemically-administered TDP-43 CYTOPE rapidly and efficiently distributed to the brain and periphery, internalized into the cytosol and significantly reduced intracellular TDP-43 pathology in an ALS mouse model TDP-43 CYTOPE meaningfully reduced intracellular TDP-43 pathology and associated RNA dysregulation caused by cryptic exon inclusions - key pathogenic features of TDP-43 proteinopathies - in a human-derived neuronal cell line Prothena Corporation plc (NASDAQ
Novo Nordisk's Phase 2 data for coramitug supports ongoing Phase 3 CLEOPATTRA clinical trial in patients with ATTR amyloidosis with cardiomyopathy Coramitug is being developed by Novo Nordisk as part of their up to $1.2 billion acquisition of Prothena's ATTR amyloidosis business and pipeline Prothena Corporation plc (NASDAQ:PRTA) announced the publication of Phase 2 clinical trial data for coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), in the American Heart Association's journal, Circulation. A link to the online publication can be found here: Coramitug, a Humanized Monoclonal
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
BofA Securities downgraded Prothena from Neutral to Underperform and set a new price target of $4.00
Oppenheimer downgraded Prothena from Outperform to Perform
Jefferies downgraded Prothena from Buy to Hold and set a new price target of $6.00
8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2025 financial results on Thursday November 6, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on November 6. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the p
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2025 financial results on Monday, August 4, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on August 4. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potent
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of deva
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena's Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb played a significant role in which she made key contributions to the Company's vision and strategy. "I would like to thank Paula for her many contributions during the past six years. As a biotechnology executive with wide-ranging global development, business strategy and commercial expertise, she provided valuable insights to the board and lea
Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2 PASA
Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory